Indaptus Therapeutics, Inc.

Company Snapshot: Indaptus Therapeutics, Inc.

Last Change Volume High Low

Company Overview

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Client News

  1. Apr 11 2024 Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
  2. Mar 28 2024 Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
  3. Mar 25 2024 Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
  4. Mar 18 2024 Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
  5. Mar 13 2024 Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
  6. Mar 4 2024 Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort